UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.) 1

Aclaris Therapeutics, Inc.
(Name of Issuer)
Common Stock, \$0.00001 par value per share
(Title of Class of Securities)
00461U105
(CUSIP Number)
January 13, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i>).

1	NAME OF REPOR	TING PERSON	
	Biotechnolog	y Value Fund, L.P.	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		2,093,085	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		2,093,085	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	2,093,085		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	3.4%		
12	TYPE OF REPORT	TING PERSON	
	PN		

1	NAME OF REPORT	TING PERSON	
1			
	BVF I GP LL	C	
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
2	CEC LICE ONLY		
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	- 1		
NUMBER OF	Delaware 5	SOLE VOTING POWER	
SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING PERSON WITH	7	2,093,085 SOLE DISPOSITIVE POWER	
PERSON WITH	/	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		0.000.005	
9	ACCDECATE AMO	2,093,085 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AMO	JUNI BENEFICIALLI OWNED DI EACH REPORTING PERSON	
	2,093,085		
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
11	I EKCENT OF CLA	SO KEI KESENTED DI AMOUNI IN KOW (3)	
	3.4%		
12	TYPE OF REPORT	ING PERSON	
	00		
	00		

1	NAME OF REPORT	TINC DEDCON	
1	NAME OF REPORT	ING PERSON	
	Riotochnology	Value Fund II, L.P.	
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
			(0) □
3	SEC USE ONLY		
3	SEC USE ONLI		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
7	CITIZENSIIII OKI	ENGL OF OROTHVEITHORY	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		1,522,970	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		1 522 070	
9	ACCDECATE AMO	1,522,970 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AIMC	JUNI BENEFICIALLI OWNED DI EACH REFORTING FERSON	
	1,522,970		
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	2.5%		
12	TYPE OF REPORT	ING PERSON	
	PN		

1	NAME OF REPORT	TINC DEDSON	1	
1	NAME OF REPORT	WANTE OF RELOCITING LEASON		
	BVF II GP LL	C		
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
_			(b) □	
			` '	
3	SEC USE ONLY			
			_	
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	Delaware 5	SOLE VOTING POWER		
SHARES	3	SOLE VOINGTOWER		
BENEFICIALLY		0		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		1,522,970		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0		
	8	SHARED DISPOSITIVE POWER		
	U	STRIKED DISTOSTITY ET OWER		
		1,522,970		
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,522,970			
10	CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
11	LENGERII OI CER	oo taltablitle bi fiinooni in non (o)		
	2.5%			
12	TYPE OF REPORT	ING PERSON		
	00			

1	NAME OF REPORT	TINC DEDCON		
1	NAME OF REPORT	NAME OF REFORTING LEASON		
	Riotechnology	Value Trading Fund OS LP		
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
2	CHECK THE ATTR	OF MATE BOX IF A WEMBER OF A GROOT	(a) ⊠ (b) □	
			(8) 🗆	
3	SEC USE ONLY			
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION		
	Cayman Island			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY OWNED BY	6	0 SHARED VOTING POWER		
EACH	б	SHARED VOTING POWER		
REPORTING		189,520		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
1210011 ((1111	,	SOLE DISTOSTITY L'I OWER		
		0		
	8	SHARED DISPOSITIVE POWER		
		189,520		
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	100 500			
10	189,520	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10	CHECK BOX II' II	IE AGGREGATE AMOUNT IN ROW (9) EACLODES CERTAIN STIARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
		· · /		
	Less than 1%			
12	TYPE OF REPORT	ING PERSON		
	PN			

1	NAME OF REPORT	TING PERSON	
	DATE D		
	BVF Partners		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (a)		
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Cayman Island	ds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		189,520	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
TERSON WITH	/	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		100 500	
9	ACCDECATE AMO	189,520 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGATE AIVIC	JUNI DENEFICIALLI OWNED DI EACH REPORTING PERSON	
	189,520		
10	CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCEME OF CLA	CC DEDDECEMPED DV AMOUNT IN DOW (0)	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 1%		
12	TYPE OF REPORT	ING PERSON	
	CO		

1	NAME OF REPORT	TING PERSON	
	BVF GP HOL	DINGS LLC	
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Delevere		
NUMBER OF	Delaware 5	SOLE VOTING POWER	
SHARES	ο	SOLE VOTING POWER	
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		3,616,055	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		3,616,055	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	3,616,055	TE A CODEC ATE A MOUNTE IN DOW! (6) EVOLVIDES CEDITA IN SULADES	
10	CHECK BOX IF IF	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	5.9%		
12	TYPE OF REPORT	ING PERSON	
	00		

1	NAME OF DEDOD	FINC DEDCOM	
1	NAME OF REPORTING PERSON		
	DI III D	T D	
	BVF Partners		
2	CHECK THE APPE	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION	
	- 1		
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		2.000.042	
PERSON WITH	7	3,868,043 SOLE DISPOSITIVE POWER	
PERSON WITH	/	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	-
	O	SHARED DISFOSITIVE FOWER	
		3,868,043	
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
3	71001tE0711E71WI	SONT BENEFICIALET OWNER BY ENGINEER ONTING PERSON	
	3,868,043		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
		•	
	6.3%		
12	TYPE OF REPORT	ING PERSON	
	PN, IA		

1	NAME OF REPORT	TINC DEDCON	1	
1	NAME OF REPORT	IVAME OF REFORMING LEASON		
	BVF Inc.			
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵	
2	CHECK THE ATTR	OTRINIE BOX II A WEWDER OF A GROOT	(a) ⊡ (b) □	
			(6) =	
3	SEC USE ONLY			
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES		0		
BENEFICIALLY OWNED BY	6	0 SHARED VOTING POWER		
EACH	0	SHARED VOTING POWER		
REPORTING		3,868,043		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	,			
		0		
	8	SHARED DISPOSITIVE POWER		
		3,868,043		
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,000,042			
10	3,868,043	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П	
10	CHECK BOX IF IT	IE AGGREGATE AMOUNT IN ROW (9) EACLODES CERTAIN SHARES		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	6.3%			
12	TYPE OF REPORTI	ING PERSON		
	CO			

1	NAME OF REPORT	TINC DEDSON		
1	NAME OF REPORT	NAME OF REFORMING LEASON		
	Mark N. Lamp	ert		
2	_	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
_		OF REFIELD BOX IF AT WILLIAM OF A GROOT	(a) □ (b) □	
			(=)	
3	SEC USE ONLY			
4	CITIZENSHIP OR F	PLACE OF ORGANIZATION		
	II.'t. I Con			
NUMBER OF	United States 5	SOLE VOTING POWER		
SHARES	3	SOLE VOTING FOWER		
BENEFICIALLY		0		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING		3,868,043		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
	8	0 SHARED DISPOSITIVE POWER		
	ŏ	SHARED DISPOSITIVE POWER		
		3,868,043		
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	3,868,043			
10	CHECK BOX IF TH	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	DEDCENT OF CLAS	CC DEDDECENTED DV AMOUNT IN DOM (0)		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	6.3%			
12	TYPE OF REPORTI	NG PERSON		
	IN			

Item 1(a). Name of Issuer:

Aclaris Therapeutics, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

640 Lee Road, Suite 200 Wayne, PA 19087

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC ("BVF GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF Partners L.P. ("Partners")

44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, \$0.00001 par value per share (the "Shares").

Item 2(e). CUSIP Number:

00461U105

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.
(j)	//	A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on January 24, 2022, (i) BVF beneficially owned 2,093,085 Shares, (ii) BVF2 beneficially owned 1,522,970 Shares and (iii) Trading Fund OS beneficially owned 189,520 Shares.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 2,093,085 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,522,970 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 189,520 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 3,616,055 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,868,043 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 62,468 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,868,043 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 3,868,043 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 61,227,333 Shares outstanding as of October 29, 2021, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2021.

As of the close of business on January 24, 2022, (i) BVF beneficially owned approximately 3.4% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.5% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 3.4% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 2.5% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 5.9% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 6.3% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF, BVF2, BVF GP and BVF2 GP. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or

Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 24, 2022

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert
Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT

16

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated January 24, 2022 with respect to the Common Stock, \$0.00001 par value per share of Aclaris Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: January 24, 2022

BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP BVF I GP LLC., its general partner By: BVF Partners L.P., its investment manager By: BVF Inc., its general partner /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF I GP LLC** BVF GP HOLDINGS LLC Bv: /s/ Mark N. Lampert /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark N. Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. By: BVF II GP LLC, its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF II GP LLC** BVF INC. By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert

BVF PARTNERS OS LTD.

Chief Executive Officer

By: BVF Partners L.P., its sole member By: BVF Inc., its general partner

By: /s/ Mark N. Lampert
Mark N. Lampert

President

/s/ Mark N. Lampert
MARK N. LAMPERT

Mark N. Lampert President